Literature DB >> 8456069

Pulmonary delivery of free and liposomal insulin.

F Y Liu1, Z Shao, D O Kildsig, A K Mitra.   

Abstract

The effects of oligomerization and liposomal entrapment on pulmonary insulin absorption were investigated in rats using an intratracheal instillation method. The results indicated that both dimeric and hexameric insulins can be rapidly absorbed into the systemic circulation, producing a significant hypoglycemic response. Intratracheal instillation of insulin in two different oligomerized states has not resulted in any significant difference in the duration of hypoglycemic effect. However, the initial hypoglycemic response (first 10 min) obtained from intratracheal administration of 25 IU/kg hexameric insulin appears to be slower than that from the 25 IU/kg dimeric insulin, thereby suggesting that hexameric insulin may have a lower permeability coefficient across alveolar epithelium than the dimeric insulin. Intratracheal administration of insulin liposomes (dipalmitoylphosphatidyl choline:cholesterol, 7:2) led to facilitated pulmonary uptake of insulin and enhanced the hypoglycemic effect. Nevertheless, similar insulin uptake and pharmacodynamic response were obtained from both the physical mixture of insulin and blank liposomes and liposomally entrapped insulin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456069     DOI: 10.1023/a:1018934810512

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Modeling absorption kinetics of subcutaneous injected soluble insulin.

Authors:  E Mosekilde; K S Jensen; C Binder; S Pramming; B Thorsteinsson
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

2.  Formation of multilayered vesicles from water/organic-solvent (w/o) emulsions: theory and practice.

Authors:  C Pidgeon; A H Hunt; K Dittrich
Journal:  Pharm Res       Date:  1986-02       Impact factor: 4.200

3.  Insulin across respiratory mucosae by aerosol delivery.

Authors:  F W Wigley; J H Londono; S H Wood; J C Shipp; R H Waldman
Journal:  Diabetes       Date:  1971-08       Impact factor: 9.461

4.  Binding of insulin to the external surface of liposomes. Effect of surface curvature, temperature, and lipid composition.

Authors:  J H Wiessner; K J Hwang
Journal:  Biochim Biophys Acta       Date:  1982-08-12

5.  Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig.

Authors:  R M Fielding; R M Abra
Journal:  Pharm Res       Date:  1992-02       Impact factor: 4.200

Review 6.  Clearance and recycling of pulmonary surfactant.

Authors:  J R Wright
Journal:  Am J Physiol       Date:  1990-08

7.  Peptide-carrier interaction: induction of liposome fusion and aggregation by insulin.

Authors:  J H Wiessner; H Mar; D G Baskin; K J Hwang
Journal:  J Pharm Sci       Date:  1986-03       Impact factor: 3.534

8.  Differential effects of anionic, cationic, nonionic, and physiologic surfactants on the dissociation, alpha-chymotryptic degradation, and enteral absorption of insulin hexamers.

Authors:  Z Shao; Y Li; R Krishnamoorthy; T Chermak; A K Mitra
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

9.  Pulmonary biotransformation of insulin in rat and rabbit.

Authors:  F Y Liu; D O Kildsig; A K Mitra
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

10.  Adenosine triphosphate liposomes: encapsulation and distribution studies.

Authors:  G X Xu; X H Xie; F Y Liu; D L Zang; D S Zheng; D J Huang; M X Huang
Journal:  Pharm Res       Date:  1990-05       Impact factor: 4.200

View more
  14 in total

1.  Influence of absorption promoters on pulmonary insulin bioactivity.

Authors:  T Mahesh Kumar; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

2.  Drug Permeation Characterization of Inhaled Dry Powder Formulations in Air-Liquid Interfaced Cell Layer Using an Improved, Simple Apparatus for Dispersion.

Authors:  Ayumu Asai; Tomoyuki Okuda; Erina Sonoda; Tomoyo Yamauchi; Saki Kato; Hirokazu Okamoto
Journal:  Pharm Res       Date:  2015-10-21       Impact factor: 4.200

Review 3.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 4.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

5.  Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats.

Authors:  Mathangi Gopalakrishnan; Sandra Suarez; Anthony J Hickey; Jogarao V S Gobburu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

6.  Effects of phospholipid chain length, concentration, charge, and vesicle size on pulmonary insulin absorption.

Authors:  Y Li; A K Mitra
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

7.  Insulin self-association: effects on lung disposition kinetics in the airways of the isolated perfused rat lung (IPRL).

Authors:  Yinuo Pang; Masahiro Sakagami; Peter R Byron
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

Review 8.  Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics.

Authors:  Masahiro Sakagami
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog.

Authors:  D B Bennett; E Tyson; C A Nerenberg; S Mah; J S de Groot; Z Teitelbaum
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

10.  Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.

Authors:  A Omri; C Beaulac; M Bouhajib; S Montplaisir; M Sharkawi; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.